Patricia Rao

US Patent:

7541443, Jun 2, 2009

Filed:

Jan 29, 2003

Appl. No.:

10/353708

Inventors:

Mark Frewin - Oxford, GB
Herman Waldmann - Oxford, GB
Scott Gorman - Witney, GB
Geoff Hale - Marston, GB
Patricia Rao - Acton MA, US
Tadeusz Kornaga - Cambridge MA, US
Douglas Ringler - Boston MA, US
Stephen Cobbold - Witney, GB

Assignee:

Tolerrx, Inc. - Cambridge MA
Isis Innovation, Ltd. - Oxford
Cambridge University Technical Services, Ltd. - Cambridge

International Classification:

C07K 16/28

US Classification:

53038875, 5303873

Abstract:

Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

US Patent:

7947272, May 24, 2011

Filed:

Jul 13, 2006

Appl. No.:

11/486293

Inventors:

Mark Frewin - Oxford, GB
Herman Waldmann - Oxford, GB
Scott Gorman - Whitney, GB
Geoff Hale - Marston, GB
Patricia Rao - Acton MA, US
Tadeusz Kornaga - Cambridge MA, US
Douglas Ringler - Boston MA, US
Stephen Cobbold - Witney, GB

Assignee:

Tolerx, Inc. - Cambridge MA
Isis Innovation, Ltd. - Oxford
Cambridge University Technical Services, Ltd. - Cambridge

International Classification:

A61K 39/395

US Classification:

4241441, 4241331

Abstract:

Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is preferably TRX1 antibody and the compound or combination is preferably used in accordance with a specified dosing regimen.

US Patent:

20020147312, Oct 10, 2002

Filed:

Jan 30, 2002

Appl. No.:

10/060714

Inventors:

Theresa O'Keefe - Waltham MA, US
Patricia Rao - Acton MA, US

International Classification:

C07K016/28

US Classification:

530/387300, 530/388150

Abstract:

Methods of providing hybrid antibodies having improved assembly characteristics are disclosed. Accordingly, the present invention provides hybrid antibodies, antigen binding fragments thereof, which include a chimeric immunoglobulin heavy chain and a humanized or CDR-grafted immunoglobulin light chain, pharmaceutical compositions thereof, as well as nucleic acids encoding the aforesaid antibodies, host cells and vectors containing such nucleic acids. Therapeutic and diagnostic uses of such hybrid antibodies molecules thereof are also disclosed.

US Patent:

20030108518, Jun 12, 2003

Filed:

Jun 13, 2002

Appl. No.:

10/171452

Inventors:

Mark Frewin - Oxford, GB
Herman Waldmann - Oxford, GB
Scott Gorman - Witney, GB
Geoff Hale - Oxford, GB
Patricia Rao - Acton MA, US
Tadeusz Kornaga - Cambridge MA, US
Douglas Ringler - Boston MA, US
Stephen Cobbold - Oxfordshire, GB

International Classification:

A61K039/395
A61K038/20
C07K016/28

US Classification:

424/085200, 424/144100, 530/388220

Abstract:

Inducing tolerance in a primate by use of a compound that has certain characteristics when tested in vitro. The compound is preferably TRX1 antibody and the compound is preferably used in accordance with a specified dosing regimen.

US Patent:

20040166099, Aug 26, 2004

Filed:

Nov 10, 2003

Appl. No.:

10/704921

Inventors:

Patricia Rao - Acton MA, US

Assignee:

TolerRx, Inc. - Cambridge MA

International Classification:

A61K048/00

US Classification:

424/093210, 514/044000

Abstract:

The present invention is based, at least in part, on the discovery of certain genes which are absent from T regulatory cells and present on effector T cells (Th1 and Th2), e.g., Protein Kinase C Theta (PKC theta). Furthermore, a pathway essential for the production of inflammatory cytokines and cellular proliferation of inflammatory, effector T cells is not utilized by regulatory T cells. Accordingly, in one aspect the invention provides. methods for promoting regulatory T cell function in immune cells relative to effector T cell function, comprising contacting immune cells with an agent that inhibits a protein kinase C theta pathway in the immune cells. In another aspect, the invention provides methods for treating a subject having a condition that would benefit from promoting regulatory T cell function relative to effector T cell function in the subject, comprising administering an agent that inhibits a protein kinase C theta pathway in immune cells of the subject. In still another aspect, the invention provides assays for screening compounds that specifically modulate a effector T cell function without modulating regulatory T cell function comprising contacting a protein kinase C theta pathway molecule with a test compound and determining the ability of the test compound to modulate the protein kinase C theta pathway molecule activity, wherein modulation of a protein kinase C theta pathway molecule activity indicates that the test compound is a specific modulator of a effector T cell function.

US Patent:

20040175381, Sep 9, 2004

Filed:

Dec 9, 2003

Appl. No.:

10/731984

Inventors:

Patricia Rao - Acton MA, US
Douglas Ringler - Cambridge MA, US

Assignee:

TolerRx, Inc. - Cambridge MA

International Classification:

A61K039/395

US Classification:

424/144100

Abstract:

The present invention is based, at least in part, on the finding that tolerance can be induced by inhibition of CD4+ and CD8+ T cells. Accordingly, the methods of the invention are useful in treating a primate, e.g., a human, by inhibiting CD4+ and CD8+ T cells to induce tolerance to at least one antigen, e.g., self or foreign, such as for inducting tolerance in a primate against a transplanted antigen, e.g., an allogeneic or xenogeneic transplanted antigen.

US Patent:

20050032725, Feb 10, 2005

Filed:

Oct 9, 2003

Appl. No.:

10/684206

Inventors:

Patricia Rao - Acton MA, US
Grazyna Szymanska - Dedham MA, US

Assignee:

ToerRx, Inc. - Cambridge MA

International Classification:

A61K048/00
A61K038/17

US Classification:

514044000, 514012000

Abstract:

The present invention is based, at least in part, on the finding that certain molecules are preferentially associated with effector T cells or regulatory T cells. Accordingly, immune responses by one or the other subset of cells can be preferentially modulated. The invention pertains, e.g., to methods of modulating (e.g., up- or down-modulating), the balance between the activation of regulatory T cells and effector T cells leading to modulation of immune responses and to compositions useful in modulating those responses. The invention also pertains to methods useful in diagnosing, treating, or preventing conditions that would benefit from modulating effector T cell function relative to regulatory T cell function or from modulating regulatory T cell function relative to effector T cell function in a subject. The subject methods and compositions are especially useful in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous effector T cell response to antigens associated with the condition, in the diagnosis, treatment or prevention of conditions characterized by a weak effector T cell response, in the diagnosis, treatment or prevention of conditions characterized by a too-vigorous regulatory T cell response, or in the diagnosis, treatment, or prevention of conditions characterized by a weak regulatory T cell response.

US Patent:

20050048587, Mar 3, 2005

Filed:

Jul 19, 2004

Appl. No.:

10/895225

Inventors:

Patricia Rao - Acton MA, US
Jessica Snyder - Newton MA, US
Andria Bagley - Boston MA, US

Assignee:

TolerRx, Inc. - Cambridge MA

International Classification:

G01N033/567

US Classification:

435007210

Abstract:

The invention provides methods (also referred to herein as a “screening assays”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) capable of modulating tolerance. In one embodiment, the invention provides methods for identifying a tolerance modulatory compound, comprising, e.g., contacting a T cell with a stimulating agent and a test compound and assaying for expression or activity of at least one T regulatory (Treg) marker and at least one T effector (Teff) marker.